Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 15;1:CCI.17.00079. doi: 10.1200/CCI.17.00079

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Fig 2. — Chemotherapy regimen network for treatment of relapsed/refractory multiple myeloma, through 2016. (A) Initial valuations, before application of propagation and refresh. The current standard of care is doublet or triplet therapy using an immunomodulatory drug or proteasome inhibitor backbone. This is reflected in the ranking, although Bort-Dex and Len-Dex are the lowest-ranked regimens. (B) Applying propagation and refresh to the network changes several valuations; most notably, Dex is much more negatively valued. Bort, bortezomib; Car, carfilzomib; Cy, cyclophosphamide; Dara, daratumumab; Dex, dexamethasone; Elo, elotuzumab; HD, high dose; Ixaz, ixazomib; LD, low dose; Len, lenalidomide; Panob, panobinostat; Pom, pomalidomide; SC, subcutaneous; Siltux, siltuximab; Thal, thalidomide; Vorin, vorinostat.